Literature DB >> 26910387

Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012.

Suzue Saito1, Philani Mpofu, E Jane Carter, Lameck Diero, Kara K Wools-Kaloustian, Constantin T Yiannoutsos, Musick S Beverly, Simon Tsiouris, Geoffrey R Somi, John Ssali, Denis Nash, Batya Elul.   

Abstract

BACKGROUND: Antiretroviral therapy (ART) reduces the risk of Tuberculosis (TB) among people living with HIV (PLWH). With ART scale-up in sub-Saharan Africa over the past decade, incidence of TB among PLWH engaged in HIV care is predicted to decline.
METHODS: We conducted a retrospective analysis of routine clinical data from 168,330 PLWH receiving care at 35 facilities in Kenya, Tanzania, and Uganda during 2003-2012, participating in the East African region of the International Epidemiologic Databases to Evaluate AIDS. Temporal trends in facility-based annual TB incidence rates (per 100,000 person years) among PLWH and country-specific standardized TB incidence ratios using annual population-level TB incidence data from the World Health Organization were computed between 2007 and 2012. We examined patient-level and facility-level factors associated with incident TB using multivariable Cox models.
RESULTS: Overall, TB incidence rates among PLWH in care declined 5-fold between 2007 and 2012 from 5960 to 985 per 100,000 person years [P = 0.0003] (Kenya: 7552 to 1115 [P = 0.0007]; Tanzania: 7153 to 635 [P = 0.0025]; Uganda: 3204 to 242 [P = 0.018]). Standardized TB incidence ratios significantly decreased in the 3 countries, indicating a narrowing gap between incidence rates among PLWH and the general population. We observed lower hazards of incident TB among PLWH on ART and/or isoniazid preventive therapy and receiving care in facilities offering TB treatment onsite.
CONCLUSIONS: Annual TB incidence rates among PLWH significantly declined during ART scale-up but remained higher than the general population. Increasing access to ART and isoniazid preventive therapy and co-location of HIV and TB treatment may further reduce TB incidence among PLWH.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26910387      PMCID: PMC5902407          DOI: 10.1097/QAI.0000000000000896

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  36 in total

1.  The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru.

Authors:  P G Suárez; C J Watt; E Alarcón; J Portocarrero; D Zavala; R Canales; F Luelmo; M A Espinal; C Dye
Journal:  J Infect Dis       Date:  2001-07-18       Impact factor: 5.226

2.  Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design.

Authors:  C Lienhardt; S Bennett; G Del Prete; O Bah-Sow; M Newport; P Gustafson; K Manneh; V Gomes; A Hill; K McAdam
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

Review 3.  A consistent log-linear relationship between tuberculosis incidence and body mass index.

Authors:  Knut Lönnroth; Brian G Williams; Peter Cegielski; Christopher Dye
Journal:  Int J Epidemiol       Date:  2009-10-09       Impact factor: 7.196

4.  Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection.

Authors:  E Girardi; G Antonucci; P Vanacore; M Libanore; I Errante; A Matteelli; G Ippolito
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

5.  Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.

Authors:  Guilherme Santoro-Lopes; Ana Maria Felix de Pinho; Lee H Harrison; Mauro Schechter
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

6.  Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study.

Authors:  Alison D Grant; Salome Charalambous; Katherine L Fielding; John H Day; Elizabeth L Corbett; Richard E Chaisson; Kevin M De Cock; Richard J Hayes; Gavin J Churchyard
Journal:  JAMA       Date:  2005-06-08       Impact factor: 56.272

7.  Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.

Authors:  Roberto Muga; Inmaculada Ferreros; Klaus Langohr; Patricia García de Olalla; Jorge Del Romero; Manuel Quintana; Ignacio Alastrue; Josefina Belda; Jordi Tor; Santiago Pérez-Hoyos; Julia Del Amo
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

8.  Integrating tuberculosis and HIV care in the primary care setting in South Africa.

Authors:  David Coetzee; Katherine Hilderbrand; Eric Goemaere; Francine Matthys; Marleen Boelaert
Journal:  Trop Med Int Health       Date:  2004-06       Impact factor: 2.622

9.  Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Authors:  Stephen D Lawn; Landon Myer; David Edwards; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

Review 10.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  6 in total

Review 1.  Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations.

Authors:  Emily Mendenhall; Brandon A Kohrt; Shane A Norris; David Ndetei; Dorairaj Prabhakaran
Journal:  Lancet       Date:  2017-03-04       Impact factor: 79.321

2.  Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.

Authors:  Khai Hoan Tram; Florence Mwangwa; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Albert Plenty; Dalsone Kwariisima; Tamara D Clark; Maya L Petersen; Edwin D Charlebois; Moses R Kamya; Gabriel Chamie; Diane V Havlir; Carina Marquez
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

3.  TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings.

Authors:  I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

4.  Association of Pulmonary Tuberculosis and HIV in the Mexican Institute of Social Security, 2006-2014.

Authors:  David Alejandro Cabrera-Gaytán; María Del Rosario Niebla-Fuentes; Rosario Padilla-Velázquez; Gabriel Valle-Alvarado; Lumumba Arriaga-Nieto; Teresita Rojas-Mendoza; Ulises Rosado-Quiab; Concepción Grajales-Muñiz; Alfonso Vallejos-Parás
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

5.  Spatial overlap links seemingly unconnected genotype-matched TB cases in rural Uganda.

Authors:  Gabriel Chamie; Midori Kato-Maeda; Devy M Emperador; Bonnie Wandera; Olive Mugagga; John Crandall; Michael Janes; Carina Marquez; Moses R Kamya; Edwin D Charlebois; Diane V Havlir
Journal:  PLoS One       Date:  2018-02-13       Impact factor: 3.240

6.  Decreased risk of HIV-associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and population-based analysis.

Authors:  Bernhard Kerschberger; Michael Schomaker; Alex Telnov; Debrah Vambe; Nicholas Kisyeri; Welile Sikhondze; Lorraine Pasipamire; Siphiwe Mavis Ngwenya; Barbara Rusch; Iza Ciglenecki; Andrew Boulle
Journal:  Trop Med Int Health       Date:  2019-08-07       Impact factor: 2.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.